XML 26 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
OPTIONS
12 Months Ended
Oct. 31, 2021
OPTIONS  
NOTE 5 - OPTIONS

NOTE 5 - OPTIONS

 

The Company, under its 2012 Stock Option Plan, issues options to various officers, directors, and consultants. The options vest in equal annual installments over a five year period with the first 20% vested when the options are granted. All of the options are exercisable at a purchase price based on the last trading price of the Company’s common stock.

 

On December 12, 2019, the Company issued 336,250 options: 120,000 to two officers, 11,250 to three independent directors and 205,000 to six employees and consultants. The options are exercisable into common stock of the Company at $0.59 per share. The Company calculated a fair value of the options of $132,673 using the Black Scholes option pricing model with computed volatility of 207%, risk-free interest rate of 2%, expected dividend yield 0%, stock price at measurement date of $0.39 and the expected term of ten years. The options are expensed over a five-year period with 20% upon issuance and 20% for the first and each subsequent year. 

 

On December 15, 2020, the Company issued 41,250 options: 11,250 to three independent directors and 30,000 to three consultants. The options are exercisable into common stock of the Company at $0.64 per share. The Company calculated a fair value of the options of $27,190 using the Black Scholes option pricing model with computed volatility of 201%, risk-free interest rate of 2%, expected dividend yield 0%, stock price at measurement date of $0.68 and the expected term of ten years. The options are expensed over a five-year period with 20% upon issuance and 20% for the first and each subsequent year. 

 

The Company has elected to amortize the options over the vesting period of the option as stock-based compensation. During the year ended October 31, 2021, the Company expensed $194,926 for options. The unrecognized future balance to be expensed over the term of the options is $132,610.

 

The number of options exercisable as of year ended October 31, 2021 was 6,081,250.

 

The following sets forth the options granted and outstanding as of October 31, 2021:

 

 

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Granted

 

 

 

 

 

 

 

 

 

Exercise

 

 

Contract

 

 

Options

 

 

Intrinsic

 

 

 

Options

 

 

Price

 

 

Life

 

 

Exercisable

 

 

Value

 

Outstanding at Year Ended October 31, 2019

 

 

7,581,400

 

 

 

0.13

 

 

 

7.19

 

 

 

5,470,540

 

 

$1,827,117

 

Granted

 

 

336,250

 

 

 

0.56

 

 

 

9.50

 

 

 

--

 

 

 

--

 

Exercised

 

 

--

 

 

 

--

 

 

 

--

 

 

 

 

 

 

 

 

 

Forfeited

 

 

--

 

 

 

--

 

 

 

--

 

 

 

--

 

 

 

--

 

Outstanding at Year Ended October 31, 2020

 

 

7,917,650

 

 

 

0.15

 

 

 

6.16

 

 

 

5,765,680

 

 

 

3,627,845

 

Granted

 

 

41,250

 

 

 

0.64

 

 

 

9.63

 

 

 

--

 

 

 

--

 

Exercised

 

 

-

 

 

 

--

 

 

 

--

 

 

 

--

 

 

 

--

 

Forfeited

 

 

--

 

 

 

--

 

 

 

--

 

 

 

--

 

 

 

--

 

Outstanding at Yar Ended October 31, 2021

 

 

7,958,900

 

 

 

0.15

 

 

 

5.16

 

 

 

6,081,250

 

 

$3,805,201